Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Höllerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU.

Sci Rep. 2017 Sep 13;7(1):11469. doi: 10.1038/s41598-017-11664-5.

2.

Recent advances in treating Parkinson's disease.

Oertel WH.

F1000Res. 2017 Mar 13;6:260. doi: 10.12688/f1000research.10100.1. eCollection 2017. Review.

3.

Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.

Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH.

Acta Neuropathol. 2017 Apr;133(4):535-545. doi: 10.1007/s00401-017-1684-z. Epub 2017 Feb 8.

4.

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Oertel WH, Hallström Y, Saletu-Zyhlarz GM, Hopp M, Bosse B, Trenkwalder C; RELOXYN Study Group.

CNS Drugs. 2016 Aug;30(8):749-60. doi: 10.1007/s40263-016-0372-1.

5.

Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.

Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, Weintraub D.

Parkinsonism Relat Disord. 2016 Jun;27:102-6. doi: 10.1016/j.parkreldis.2016.03.006. Epub 2016 Mar 12.

6.

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.

Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU; AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group.

Mov Disord. 2016 May;31(5):742-7. doi: 10.1002/mds.26580. Epub 2016 Mar 7. Review.

7.

DTI and VBM reveal white matter changes without associated gray matter changes in patients with idiopathic restless legs syndrome.

Belke M, Heverhagen JT, Keil B, Rosenow F, Oertel WH, Stiasny-Kolster K, Knake S, Menzler K.

Brain Behav. 2015 Sep;5(9):e00327. doi: 10.1002/brb3.327. Epub 2015 Jul 30.

8.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, Marek K; PPMI Sleep Working group on behalf of the PPMI Investigators.

Mov Disord. 2015 Sep;30(10):1371-81. doi: 10.1002/mds.26248. Epub 2015 Jun 11.

9.

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types.

Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, Mollenhauer B, Scherzer CR, Ivinson AJ, Finke C, Schöls L, Müller Vom Hagen J, Trenkwalder C, Jahn H, Höltje M, Biswal BB, Harms L, Ruprecht K, Buchert R, Höglinger GU, Oertel WH, Unger MM, Körtvélyessy P, Bittner D, Priller J, Spruth EJ, Paul F, Meisel A, Lynch DR, Dirnagl U, Endres M, Teegen B, Probst C, Komorowski L, Stöcker W, Dalmau J, Prüss H.

Ann Clin Transl Neurol. 2014 Oct;1(10):822-32. doi: 10.1002/acn3.120. Epub 2014 Oct 18.

10.

Piericidin A aggravates Tau pathology in P301S transgenic mice.

Höllerhage M, Deck R, De Andrade A, Respondek G, Xu H, Rösler TW, Salama M, Carlsson T, Yamada ES, Gad El Hak SA, Goedert M, Oertel WH, Höglinger GU.

PLoS One. 2014 Dec 1;9(12):e113557. doi: 10.1371/journal.pone.0113557. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122907.

11.

Diesterified derivatives of 5-iodo-2'-deoxyuridine as cerebral tumor tracers.

Rösler TW, Matusch A, Librizzi D, Arias-Carrión O, Freundlieb N, Hoeffken H, Oertel WH, Depboylu C, Höglinger GU.

PLoS One. 2014 Jul 16;9(7):e102397. doi: 10.1371/journal.pone.0102397. eCollection 2014.

12.

Targeted resequencing and systematic in vivo functional testing identifies rare variants in MEIS1 as significant contributors to restless legs syndrome.

Schulte EC, Kousi M, Tan PL, Tilch E, Knauf F, Lichtner P, Trenkwalder C, Högl B, Frauscher B, Berger K, Fietze I, Hornyak M, Oertel WH, Bachmann CG, Zimprich A, Peters A, Gieger C, Meitinger T, Müller-Myhsok B, Katsanis N, Winkelmann J.

Am J Hum Genet. 2014 Jul 3;95(1):85-95. doi: 10.1016/j.ajhg.2014.06.005.

13.

Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.

O'Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, Tolosa E, Sherwin PF, Grachev ID.

BMJ Open. 2014 Jul 3;4(7):e005122. doi: 10.1136/bmjopen-2014-005122.

14.

Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.

Noelker C, Morel L, Osterloh A, Alvarez-Fischer D, Lescot T, Breloer M, Gold M, Oertel WH, Henze C, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A.

J Neuroinflammation. 2014 May 8;11:86. doi: 10.1186/1742-2094-11-86.

15.

Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model.

Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C, Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A.

PLoS One. 2013 Apr 18;8(4):e61700. doi: 10.1371/journal.pone.0061700. Print 2013.

16.

Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease.

Dams J, Klotsche J, Bornschein B, Reese JP, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel WH, Deuschl G, Siebert U, Dodel R.

Health Qual Life Outcomes. 2013 Mar 8;11:35. doi: 10.1186/1477-7525-11-35.

17.

Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.

Becker A, Ludwig N, Keller A, Tackenberg B, Eienbröker C, Oertel WH, Fassbender K, Meese E, Ruprecht K.

PLoS One. 2013;8(3):e58095. doi: 10.1371/journal.pone.0058095. Epub 2013 Mar 4.

18.

Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment.

Mengel D, Röskam S, Neff F, Balakrishnan K, Deuster O, Gold M, Oertel WH, Bacher M, Bach JP, Dodel R.

Transl Psychiatry. 2013 Mar 5;3:e236. doi: 10.1038/tp.2012.151.

19.

Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease).

Schorlemmer K, Bauer S, Belke M, Hermsen A, Klein KM, Reif PS, Oertel WH, Kunz WS, Knake S, Rosenow F, Strzelczyk A.

Epilepsy Behav Case Rep. 2013 Aug 16;1:118-21. doi: 10.1016/j.ebcr.2013.07.003. eCollection 2013.

20.

Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease.

Marx S, Respondek G, Stamelou M, Dowiasch S, Stoll J, Bremmer F, Oertel WH, Höglinger GU, Einhäuser W.

Front Behav Neurosci. 2012 Dec 13;6:88. doi: 10.3389/fnbeh.2012.00088. eCollection 2012.

Supplemental Content

Loading ...
Support Center